Found: 9
Select item for more details and to access through your institution.
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 4, p. 450, doi. 10.3390/jcm8040450
- By:
- Publication type:
- Article
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study.
- Published in:
- Cancers, 2024, v. 16, n. 17, p. 3037, doi. 10.3390/cancers16173037
- By:
- Publication type:
- Article
Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 8, p. 9097, doi. 10.1002/cam4.5647
- By:
- Publication type:
- Article
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 4, p. 1521, doi. 10.1002/cam4.2037
- By:
- Publication type:
- Article
Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma.
- Published in:
- Respirology Case Reports, 2018, v. 6, n. 8, p. 1, doi. 10.1002/rcr2.372
- By:
- Publication type:
- Article
Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-74573-0
- By:
- Publication type:
- Article
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00350-7
- By:
- Publication type:
- Article
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
- Published in:
- Targeted Oncology, 2024, v. 19, n. 3, p. 423, doi. 10.1007/s11523-024-01048-x
- By:
- Publication type:
- Article
Initial AXL and MCL‐1 inhibition contributes to abolishing lazertinib tolerance in EGFR‐mutant lung cancer cells.
- Published in:
- Cancer Science, 2024, v. 115, n. 10, p. 3333, doi. 10.1111/cas.16292
- By:
- Publication type:
- Article